Search Results for: ustr

KEI has asked 21 persons following the TPP IPR negotiations, what they thought of four of the USTR negotiators, including:

• Ambassador and USTR head Michael Froman,
• TPP Chief negotiator Barbara Weisel
• Assistant USTR for Intellectual Property and Innovation Stanford McCoy, and
• Deputy Assistant USTR for Intellectual Property and Innovation Probir Mehta.

Continue Reading →

On 7-8 August 2013, the Department of Trade and Industry (the DTI), Republic of South Africa and the World Trade Organization (WTO), in close collaboration with the World Health Organization (WHO) and the World Intellectual Property Organization (WIPO) will hold a National Workshop on Intellectual Property and Public Health in Pretoria. Leading experts from these intergovernmental organizations, Roger Kampf (WTO), Dr. Continue Reading →

22 July 2013

This was the statement delivered by Australia (Ian Goss, General Manager, IP Australia) on Monday, 22 July 2013.

Australian Statement

Thank you chair

Firstly, I will begin with a negative, last week was perhaps the most frustrating of our meetings this year, in contrast to significant progress on Gr’s [genetic resources] with disclosure proponents agreeing on an administrative approach to disclosure rather than substantive examination, this was a significant shift in position from a number key countries.

Continue Reading →

A PDF version of our comments is available here.

People have until midnight May 10, 2013 to file comments, here:
http://www.regulations.gov/#!documentDetail;D=USTR-2013-0019-0001

This is the table of contents.

Comments on the Administration’s Intention to Enter Into Negotiations for the Transatlantic Trade and Investment Partnership (TTIP) Agreement
Response to Docket No. USTR-2013-0019

Introduction
Transparency
Continue Reading →

Below is the PhRMA press release on the Special 301 Report.

Key points in the PhRMA release:

* PhRMA “dismayed that USTR did not grant an out-of-cycle review for India.” PhRMA claims that India decisions involving German owned Bayer and Swiss owned Novartis “disproportionately impacted U.S. biopharmaceutical companies.” (Perhaps PhRMA could have said, companies that have ownership claims on the US government).

Continue Reading →

Today USTR held a one hour “listening session” with several Washington, DC public interest groups. The topic was the Transatlantic Trade and Investment Partnership (TTIP) with the European Union.

Continue Reading →

On 1 May 2013, USTR released its 2013 Special 301 Report. Ukraine was put on the Priority Foreign Country list this year, a designation not used by USTR for several years. USTR’s 2013 report spends more than six pages discussing China and two full pages on India. Below are some comments regarding this year’s report.

Least Developed Countries
Continue Reading →